Keryx Biopharmaceuticals CFO James F. Oliviero III Sells 2,087 Shares (KERX)
Keryx Biopharmaceuticals (NASDAQ:KERX) CFO James F. Oliviero III sold 2,087 shares of the company’s stock on the open market in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $16.46, for a total transaction of $34,352.02. Following the sale, the chief financial officer now directly owns 302,330 shares of the company’s stock, valued at approximately $4,976,352. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
A number of analysts have recently weighed in on KERX shares. Analysts at Ladenburg Thalmann raised their price target on shares of Keryx Biopharmaceuticals from $24.00 to $30.00 in a research note on Friday. They now have a “buy” rating on the stock. Separately, analysts at HC Wainwright reiterated a “buy” rating on shares of Keryx Biopharmaceuticals in a research note on Wednesday, April 2nd. Finally, analysts at Mizuho raised their price target on shares of Keryx Biopharmaceuticals from $25.00 to $34.00 in a research note on Wednesday, April 2nd. They now have a “buy” rating on the stock. Nine investment analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average target price of $26.43.
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) traded down 0.75% during mid-day trading on Monday, hitting $15.80. The stock had a trading volume of 2,606,427 shares. Keryx Biopharmaceuticals has a 52-week low of $6.61 and a 52-week high of $17.46. The stock has a 50-day moving average of $15.83 and a 200-day moving average of $13.40. The company’s market cap is $1.436 billion.
Keryx Biopharmaceuticals (NASDAQ:KERX) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.21) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.16) by $0.05. During the same quarter in the prior year, the company posted ($0.09) earnings per share. On average, analysts predict that Keryx Biopharmaceuticals will post $-0.50 earnings per share for the current fiscal year.
Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is focused on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.